Iadademstat Dihydrochloride is a potent, selective LSD1 inhibitor currently in development for the treatment of various cancers, including acute myeloid leukemia and small cell lung cancer. By targeting… Read more
Iadademstat Dihydrochloride is a potent, selective LSD1 inhibitor currently in development for the treatment of various cancers, including acute myeloid leukemia and small cell lung cancer. By targeting lysine-specific demethylase 1, this epigenetic therapeutic modulates gene expression programs to inhibit cancer cell proliferation and promote cell differentiation. This category features comprehensive reference standards for Iadademstat Dihydrochloride, including its related impurities, metabolites, and stable isotope-labelled compounds. These reference materials are essential for pharmaceutical laboratories conducting rigorous analytical testing, impurity profiling, and method validation. By providing reliable benchmarks for identification and quantification, these compounds support critical quality control processes and ensure data integrity in bioanalytical studies and regulatory documentation. Laboratories utilize these standards to maintain the precision and reproducibility of their scientific workflows throughout the drug development lifecycle.